Chemistry:18-Methylaminocoronaridine
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H29N3O2 |
| Molar mass | 367.493 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
(−)-18-Methylaminocoronaridine (18-MAC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont.[1][2]
See also
- 2-Methoxyethyl-18-methoxycoronaridinate
- 18-Methoxycoronaridine
- Coronaridine
- Ibogaine
- Noribogaine
- Voacangine
References
- ↑ "Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents". Journal of Medicinal Chemistry 46 (13): 2716–30. June 2003. doi:10.1021/jm020562o. PMID 12801235.
- ↑ "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology 492 (2–3): 159–67. May 2004. doi:10.1016/j.ejphar.2004.03.062. PMID 15178360.
 |  |
